{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:19:33Z","timestamp":1785410373165,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020048","name":"Milky Way Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032490","name":"Freedom Together Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032490","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017023","name":"The Paul G Allen Frontiers Group","doi-asserted-by":"publisher","award":["19PABH134610000"],"award-info":[{"award-number":["19PABH134610000"]}],"id":[{"id":"10.13039\/100017023","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bmc.2025.118196","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T12:22:21Z","timestamp":1744806141000},"page":"118196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Scaffold hopping and sidechain modification from a flavone scaffold lead to discovery of potent, selective CK2A2 inhibitors with favorable properties for CNS activity"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-2294","authenticated-orcid":false,"given":"James K.","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana I.N.","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred H.","family":"Gage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118196_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: a potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118196_b0010","unstructured":"(a) Niefind, K.; Guerra, B.; Ermakowa, I. et al. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 2001, 20, 5320-5331. https:\/\/doi.org\/10.1093\/emboj\/20.19.5320. (b) CK2A1 may appear in other sources as CK2\u03b1, CK2\u03b11, or CK2alpha1 and is encoded by the CSNK2A1 gene. CK2A2 may appear in other sources as CK2\u03b1\u2019, CK2\u03b12, or CK2alpha2 and is encoded by the CSNK2A2 gene. CK2B may appear in other sources as CK2\u03b2 or CK2beta and is encoded by the CSNK2B gene."},{"key":"10.1016\/j.bmc.2025.118196_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11010-011-0948-5","article-title":"Enzymatic activity with an incomplete catalytic spine: insights from a comparative structural analysis of human CK2A and its paralogous isoform CK2A\u2019","volume":"356","author":"Bischoff","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.bmc.2025.118196_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2011.01.020","article-title":"Structure of the human protein kinase CK2 catalytic subunit CK2\u03b1\u2019 and interaction thermodynamics with the regulatory subunit CK2\u03b2","volume":"407","author":"Bischoff","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2025.118196_b0025","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1242\/jcs.00074","article-title":"Protein kinase CK2: a challenge to canons","volume":"115","author":"Pinna","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bmc.2025.118196_b0030","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00018-017-2705-8","article-title":"Re-evaluation of protein kinase CK2 pleiotropy: new insights provided by a phosphoproteomics analysis of CK2 knockout cells","volume":"75","author":"Franchin","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2025.118196_b0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.febslet.2010.11.019","article-title":"Structural basis of CX-4945 binding to human protein kinase CK2","volume":"585","author":"Ferguson","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2025.118196_b0040","first-page":"70","article-title":"The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies","volume":"31","author":"Chon","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118196_b0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2018.04.006","article-title":"CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation","volume":"45","author":"Perea","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bmc.2025.118196_b0050","unstructured":"Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application. clinicaltrials.gov. Identifier: NCT01639625. Accessed January 17, 2025."},{"key":"10.1016\/j.bmc.2025.118196_b0055","unstructured":"Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors. Clinicaltrials.gov. Identifier: NCT06541262. Accessed January 17, 2025."},{"key":"10.1016\/j.bmc.2025.118196_b0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/jbc.275.1.390","article-title":"Constitutive phosphorylation of the Parkinson\u2019s disease associated alpha-synuclein","volume":"275","author":"Okochi","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnmol.2018.00146","article-title":"CK2 phosphorylating I2PP2A\/SET mediates tau pathology and cognitive impairment","volume":"11","author":"Zhang","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bmc.2025.118196_b0070","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41419-021-04062-3","article-title":"Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer\u2019s disease","volume":"12","author":"Bettegazzi","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2025.118196_b0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-022-01331-w","article-title":"Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization","volume":"10","author":"Marshall","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.bmc.2025.118196_h0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12974-015-0470-x","article-title":"Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer\u2019s disease pathology","volume":"13","author":"Rosenberger","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.bmc.2025.118196_h0085","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.824956","article-title":"Evaluation of a Selective Chemical Probe Validates That CK2 Mediates Neuroinflammation in a Human Induced Pluripotent Stem Cell-Derived Microglial Model","volume":"15","author":"Mishra","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bmc.2025.118196_b0085","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/biomedicines10081979","article-title":"Protien Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington\u2019s Disease","volume":"10","author":"White","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2025.118196_b0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/12729","article-title":"Globozoospermia in mice lacking the casein kinase II alpha\u2019 catalytic subunit","volume":"23","author":"Xu","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.bmc.2025.118196_b0095","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/srep03460","article-title":"Global screening of CK2 kinase substrates by an integrated phosphoproteomics workflow","volume":"3","author":"Bian","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118196_b0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fcell.2017.00097","article-title":"Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics","volume":"5","author":"Rusin","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bmc.2025.118196_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021469","article-title":"Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death","volume":"369","author":"Litchfield","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2025.118196_b0110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.chembiol.2020.12.013","article-title":"Development of a potent and selective chemical probe for the pleiotropic kinase CK2","volume":"28","author":"Wells","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2025.118196_b0115","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS Drug Design: Balancing Physiochemical Properties for Optimal Brain Exposure","volume":"6","author":"Rankovic","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nature Rev Drug Disc"},{"key":"10.1016\/j.bmc.2025.118196_b0125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.5b00452","article-title":"Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Signalling Pathway in Vivo","volume":"7","author":"Dowling","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118196_b0130","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/acschembio.2c00378","article-title":"Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like \u03b2-Coronaviruses","volume":"17","author":"Yang","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2025.118196_b0135","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/molecules29174158","article-title":"Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2","volume":"29","author":"Ong","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118196_b0140","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1039\/C7SC05122K","article-title":"Second-Generation CK2\u03b1 inhibitors targeting the \u03b1D pocket","volume":"9","author":"Legre","year":"2018","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2025.118196_b0145","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/acs.jmedchem.1c00063","article-title":"Molecular Plasticity of Crystalline CK2\u03b1\u2019 Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity","volume":"65","author":"Lindenblatt","year":"2022","journal-title":"J Med Chem"},{"key":"#cr-split#-10.1016\/j.bmc.2025.118196_b0150.1","doi-asserted-by":"crossref","unstructured":"O'Brien, S. E. et al. Discovery and SAR of 5-(3 Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer. J Med Chem, 2011, 54, 635-654. https:\/\/doi.org\/10.1021\/jm101251q. (b) A separate measurement found CX-4945 inhibited both CK2A1 and CK2A2 with IC50 = 1 nM in both cases: Siddiqui-Jain, A.","DOI":"10.1021\/jm101251q"},{"key":"#cr-split#-10.1016\/j.bmc.2025.118196_b0150.2","doi-asserted-by":"crossref","unstructured":"Streiner, N. et al. CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Res., 2010, 70(24), 10288-10298. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1893.","DOI":"10.1158\/0008-5472.CAN-10-1893"},{"key":"#cr-split#-10.1016\/j.bmc.2025.118196_b0150.3","doi-asserted-by":"crossref","unstructured":"(a) Pierre, F.; Chua, P. C.; O'Brien, S. E. et al. Discovery and SAR of 5-(3 Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer. J Med Chem, 2011, 54, 635-654. https:\/\/doi.org\/10.1021\/jm101251q.","DOI":"10.1021\/jm101251q"},{"key":"#cr-split#-10.1016\/j.bmc.2025.118196_b0150.4","doi-asserted-by":"crossref","unstructured":"(b) A separate measurement found CX-4945 inhibited both CK2A1 and CK2A2 with IC50 = 1 nM in both cases: Siddiqui-Jain, A.; Drygin, D.; Streiner, N. et al. CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Res., 2010, 70(24), 10288-10298. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1893.","DOI":"10.1158\/0008-5472.CAN-10-1893"},{"key":"10.1016\/j.bmc.2025.118196_b0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phytochem.2016.12.018","article-title":"Selected flavonoid compounds as promising inhibitors of protein kinase CK2\u03b1 and CK2\u03b1\u2019, the catalytic subunits of CK2","volume":"136","author":"Baier","year":"2017","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bmc.2025.118196_b0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-011-0945-8","article-title":"Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2","volume":"356","author":"Golub","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.bmc.2025.118196_b0165","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1016\/j.bmc.2013.08.013","article-title":"Discovery and characterization of synthetic 4\u2019-hydroxyflavones\u2014New CK2 inhibitors from flavone family","volume":"21","author":"Golub","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118196_b0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejmech.2014.03.047","article-title":"Chromones as a privileged scaffold in drug discovery: A review","volume":"78","author":"Keri","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0175","series-title":"Studies in Natural Products Chemistry","first-page":"29","article-title":"An Overview of Synthetic and Semisynthetic Flavonoid Derivatives and Analogues: Perspectives in Drug Discovery","author":"Uivarosi","year":"2019"},{"key":"10.1016\/j.bmc.2025.118196_b0180","article-title":"Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy","volume":"141","author":"McCarthy","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.bmc.2025.118196_b0185","unstructured":"(a) CK2alpha1 (CSNK2A1) Human Other Protein Kinase Enzymatic Radiometric [Km ATP] KinaseProfiler LeadHunter Assay \u2013 FR. https:\/\/www.eurofinsdiscovery.com\/catalog\/ck2alpha1-csnk2a1-human-other-protein-kinase-enzymatic-radiometric-assay-km-atp-kinaseprofiler\/14-197KP (accessed 2025-01-22). (b) CK2alpha2 (CSNK2A2) Human Other Protein Kinase Enzymatic Radiometric [Km ATP] KinaseProfiler LeadHunter Assay \u2013 FR. https:\/\/www.eurofinsdiscovery.com\/catalog\/ck2alpha2-csnk2a2-human-other-protein-kinase-enzymatic-radiometric-km-atp-kinaseprofiler-leadhunter-assay-fr\/14-689KP (accessed 2025-01-22)."},{"key":"10.1016\/j.bmc.2025.118196_b0190","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1021\/bi300531c","article-title":"Inhibition of protein kinase CK2 by flavonoids and tryphostins. A Structural Insight","volume":"51","author":"Lolli","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2025.118196_b0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ph10010009","article-title":"Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor","volume":"10","author":"Niefind","year":"2017","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2025.118196_b0200","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/jm980435l","article-title":"2,6-difluorophenol as a Bioisostere of a Carboxylic Acid: Bioisosteric Analogues of y-Aminobutyric Acid","volume":"42","author":"Qiu","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104062","article-title":"Flavone inspired discovery of benzylidenebenzofuran-3(2H)-ones (aurones) as potent inhibitors of human protein kinase CK2","volume":"102","author":"Protopopov","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0210","doi-asserted-by":"crossref","first-page":"18025","DOI":"10.1021\/acs.jmedchem.1c01382","article-title":"Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4\/ Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0215","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1021\/acsomega.8b03415","article-title":"Diacritic Binding of an Indenoindole Inhibitor by CK2\u03b1 Paralogs Explored by a Reliable Path to Atomic Resolution of CK2\u03b1\u2019 Structures","volume":"4","author":"Lindenblatt","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118196_b0220","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/jo01066a039","article-title":"Acidity Constants of Some Arylimidazoles and Their Cations","volume":"26","author":"Walba","year":"1961","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2025.118196_b0225","unstructured":"pKa Values Compilation (by Dave Evans and D. H. Ripin). https:\/\/organicchemistrydata.org\/hansreich\/resources\/pka\/pka_data\/evans_pKa_table.pdf (accessed 2025-02-11)."},{"key":"10.1016\/j.bmc.2025.118196_b0230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bpj.2011.12.024","article-title":"Comprehensive Determination of Protein Tyrosine pKa Values for Photoactive Yellow Protein Using Indirect 13C NMR Spectroscopy","volume":"102","author":"Oktaviani","year":"2012","journal-title":"Biophys J"},{"key":"10.1016\/j.bmc.2025.118196_b0235","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1021\/acs.biochem.8b00217","article-title":"Hydrogen Bonds: Simple after All?","volume":"57","author":"Herschlag","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2025.118196_b0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/molecules24030405","article-title":"pKa Determination of a Histidine Residue in a Short Peptide Using Raman Spectroscopy","volume":"24","author":"Pogostin","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118196_b0245","series-title":"Theory and Practice of CNS Drug Design","author":"Rankovic","year":"2019"},{"key":"10.1016\/j.bmc.2025.118196_b0250","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.bmc.2025.118196_b0255","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2025.118196_b0260","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2478\/acph-2019-0024","article-title":"Metabolic stability and its role in the discovery of new chemical entities","volume":"69","author":"Sloczynska","year":"2019","journal-title":"Acta Pharm"},{"key":"10.1016\/j.bmc.2025.118196_b0265","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.36922\/td.4571","article-title":"Deregulation of Casein Kinase-2 in non-small-cell lung cancer: A subunit-specific analysis","volume":"3","author":"P\u00e9rez","year":"2024","journal-title":"Tumor Discov"},{"key":"10.1016\/j.bmc.2025.118196_b0270","unstructured":"TIER 1 ADME PANEL \u2013 US. https:\/\/www.eurofinsdiscovery.com\/catalog\/tier-1-adme-panel-us\/P375 (accessed 2025-02-01)."},{"key":"10.1016\/j.bmc.2025.118196_b0275","doi-asserted-by":"crossref","unstructured":"(a) Fabian, M. A.; Biggs III, W. H.; Treiber, D. K. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol, 2005, 23, 329-336. https:\/\/doi.org\/10.1038\/nbt1068. (b) Davis, M. I.; Hunt, J. P.; Herrgard, S. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29(11), 1046-1051. https:\/\/doi.org\/10.1038\/nbt.1990. (c) scanMAX Kinase Assay Panel. https:\/\/www.eurofinsdiscovery.com\/solution\/scanmax (accessed 2025-01-22).","DOI":"10.1038\/nbt.1990"},{"key":"10.1016\/j.bmc.2025.118196_b0280","unstructured":"CHEMPARTNER: DEDICATED TO LIFE SCIENCE. https:\/\/chempartner.com\/ (last accessed 2025-02-01)."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:56:53Z","timestamp":1762347413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625001373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"alternative-id":["S0968089625001373"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118196","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scaffold hopping and sidechain modification from a flavone scaffold lead to discovery of potent, selective CK2A2 inhibitors with favorable properties for CNS activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118196"}}